June 2008 clinical trials update

By Jim Hughes
LRG Science Coordinator

AMN107 Phase III:

This trial has met accrual goals and enrollment is now closed.

Sunitinib or Imatinib:

Five new sites have been added in the United States. Four new international sites have also been added:

1. Lai Chi Kok, Kowloon, Hong Kong
2. Tuen Mun, New Territories, Hong Kong
3. Milano, Italy, 20133,
4. Seoul, Republic of Korea, 135-710

Imatinib + Pegylated Interferon-a 2B:

This trial now has an NCT number and the contact information has changed. Contact Jessica Moehle, 801-587-4438 at the Huntsman Cancer Institute.

Sorafenib Phase II:

Contact information has been updated. Perifosine + Sunitinib: Trial is ongoing but not recruiting.

To view the latest clinical trials, visit: http://www.liferaftgroup.org/docs/gist_clinical_trial_datasheets.htm